MAPK1 and renal cell carcinoma: A high level of SF2, a new oncoprotein in RCC, is highly associated with a poor prognosis in a large cohort of RCC specimens, and SF2 may stimulate the proliferation of RCC cells by boosting the expression of P-AKT and phosphorylated ERK (P-ERK).